Benipath
Benipath Uses, Dosage, Side Effects, Food Interaction and all others data.
Benipath has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride. It is a synthetic dihydropyridine derivative that has anti-hypertensive and anti-anginal actions. It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.
Benipath reduces systolic and diastolic blood pressure as well as to present decreases in heart rate pulse after treatment. It is reported also a decrease urinary protein excretion and serum triglycerides. Different studies have shown benidipine anti-oxidative activity, stimulation of NO production, suppression of adhesion molecules expression, stimulation of osteoblast differentiation, suppression of the proliferation of vascular smooth muscle cells and mesangial cells, as well as myocardial protection. The enhancement of NO production is associated with the cardioprotective and antiartheriosclerotic effects of benidipine.
| Trade Name | Benipath |
| Generic | Benidipine |
| Benidipine Other Names | Benidipine |
| Weight | 8mg, 4mg |
| Type | Tablet |
| Formula | C28H31N3O6 |
| Weight | Average: 505.571 Monoisotopic: 505.22128573 |
| Protein binding | Benidipine is highly bound to plasma proteins and the bound form can account for even 98% of the administered dose. |
| Groups | Experimental |
| Therapeutic Class | |
| Manufacturer | Lupin |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Benipath is a synthetic dihydropyridine calcium channel blocker used to treat hypertension and angina pectoris.
Benipath is a potent and long-lasting drug indicated for the treatment of cardiovascular diseases such as hypertension, renoparenchymal hypertension and angina pectoris.
Benipath is also used to associated treatment for these conditions: Angina Pectoris, High Blood Pressure (Hypertension), Hypertension, Renal, Renal parenchymal hypertension
How Benipath works
Benipath is a tripe calcium channel inhibitor by inhibiting L, N and T type calcium channel. It presents a very long-lasting activity that can be explained by its high affinity for cell membranes from the DHP binding site; this characteristic indicated a long-lasting pharmacological activity of benidipine. The additional property of benidipine is the vascular selectivity towards peripheral blood vessels.
Toxicity
In preclinical studies, the LD50 of benidipine ranged from 87-384 mg/kg which is more than 100 times the needed dose to achieve anti-hypertensive action. There were no significant changes in histopathological heart examination. Benipath showed no carcinogenic, antigenicity, teratogenic or mutagenic properties.
Volume of Distribution
Benipath is highly distributed to the tissues mainly in the liver and kidneys and plasma. It does not present a high accumulation following repeated oral administrations.
Elimination Route
Benipath is rapidly absorbed after oral administration reaching a maximum concentration within 2 hours. The short period of time needed for maximum concentration to get reached is a particular characteristic of benidipine when compared with other calcium channel blockers. The registered maximum concentration and AUC are dose-dependent and it can go from 0.55-3.89 ng/ml and 1.04-6.7 ng.h/ml respectively when administered in a dose of 2-8 mg.
Half Life
The elimination half-life of benidipine is registered to be of approximate 1 hour.
Elimination Route
The percentage of urinary excretion after oral administration is of approximate 36% of the administered dose. Most of the remaining dose is excreted in feces, making bile excretion the major elimination pathway of benidipine. From the eliminated drug, none of it is expressed in the form of the unchanged drug.
Innovators Monograph
You find simplified version here Benipath
